This review introduces a new concept``Programmed Packaging'' to develop a non-viral gene delivery system. Based on this concept, multifunctional envelope type nano devices (MEND) were developed for in vitro, in situ and in vivo conditions. A quantitative study to identify a rate limiting step in intracellular tra‹cking was also shown between viral and non-viral vectors, which indicated an important role of controlled intranuclear disposition for development a safe and e‹cient non-viral gene delivery system. This review will provide a future direction of non-viral gene delivery system. 
The MEND consists of condensed nucleotides core, coated with a lipid envelope equipped with functional devices, such as polyethylene glycol (PEG) for long blood circulation, pH-sensitive fusogenic peptide for endosomal escape and protein transduction domain peptide for cellular entry. The SUV -fusion method consists of three steps, i.e., 1) DNA condensation with a polycation, 2) electrostatic interaction of the charged SUV with a DNA/polycation complex (DPC), and 3) lipid coating of the DPC due to fusion of the SUVby detergent removal. After lipid coating, the MEND can be equipped with various functional devices, such as Tf and GALA peptides.
Fig. 4. Construction of MEND by a Lipid Film Hydration Method
In this method, a condensed DNA core particle electrostatically adsorb to surface of lipidˆlm, then the core particle is coated with lipid membrane by gentle sonication. After lipid coating, the MEND can be modiˆed with functional devices, such as STR-R8. (1) Receptor-mediated endocytosis: the MEND, which is equipped with functional devices, such as targeting ligand and fusion peptide, binds to speciˆc receptor on cell surface, and internalizes via receptor-mediated endocytosis. Then, condensed core can escape from endosome by some mechanism, such as membrane fusion, and the core transfers into nucleus.
(2) Non-classical endocytosis: the MEND modiˆed with cell penetrating peptide internalizes via non-classical endocytic mechanism, which can avoid lysosomal degradation, and the core particle can transfer into nucleus after removal of envelope. The transfection e‹ciencies of R8-MEND and Adenovirus were compared using HeLa cell lines that express receptors for adenovirus serotype 5 (i.e., CAR and the integrin receptor). Increasing the dose of Adenovirus up to 1×10 5 particles/cell resulted in higher transfection e‹ciency; however, toxicity increased and transfection e‹ciency decreased at doses higher than 1 ×10 5 particles/cell. Transfection e‹ciency with R8-MEND equaled the highest transfection e‹ciency with Adenovirus, however, R8-MEND produced no detectable cytotoxicity (data not shown). To establish a potent mitochondrial drug delivery system, the drug must be encapsulated in a drug carrier depending on the physical characteristics (1). Thereafter, intracellular tra‹cking of the carrier including endosomal escape (2) and subsequent mitochondrial targeting (3) must be regulated. Tf modiˆed liposomes equipped with GALA can be internalized by tumor cells via receptor-mediated endocytosis (1). In the endosomes, GALA can enhance the fusion between liposomes and ensosomes at a lower pH and mastoparan is released to the cytosol (2). Mastoparan that escapes from the endosomes can attack the mitochondria, permeability transition is induced, and cytochrome c is released from the mitochondria (3). For drug therapy, regulation of both the bio distribution and intracellular tra‹cking are important factors. In addition, we propose``Regulation of intramitochondrial tra‹cking'' to eŠectively achieve a mitochondrial disease therapy. Sorting of a drug to the appropriate region in a mitochondrion can increase therapeutic eŠect and decrease undesired side-eŠects of that drug. 
